These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 8517647)

  • 1. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
    Watanabe A; Kuriyama H; Kiyota T
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
    Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
    Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of antitumor activity of pirarubicin by chlorpromazine in mice bearing doxorubicin-resistant P388 leukemia.
    Shibata H; Maekawa I; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):359-62. PubMed ID: 2093213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
    Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
    Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
    Chandrasekaran B; Dimling J; Capizzi RL
    Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
    Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
    J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
    Dai ZQ; Xu JY; Yuan XJ; Cai JC
    Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
    Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
    Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
    Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
    Noviello E; Allievi E; Russo P; Parodi S
    Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.
    Sadzuka Y; Egawa Y; Sugiyama T; Sawanishi H; Miyamoto K; Sonobe T
    Jpn J Cancer Res; 2000 Jun; 91(6):651-7. PubMed ID: 10874219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.